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ABSTRACT
Nutritional status in patients with neuroendocrine tumours (NETs), especially of gastroenteropancreatic
origin, can be deeply affected by excessive production of gastrointestinal hormones, peptides, and amines,
which can lead to malabsorption, diarrhoea, steatorrhea, and altered gastrointestinal motility. Besides, the
surgical and/or medical management of NETs can lead to alteration of gastrointestinal secretory, motor,
and absorptive functions, with both dietary and nutritional consequences. Indeed, disease-related
malnutrition is a frequently encountered yet both underrecognized and understudied clinical
phenomenon in patients with NETs, with substantial prognostic and socioeconomic consequences. Most of
these conditions can be alleviated by a tailored nutritional approach, also with the aim of improving the
efﬁcacy of cancer treatments. In this setting, skilled nutritionists can play a fundamental role in the
multidisciplinary health care team in NETs management and their presence should be recommended.
The aim of this review is to provide dietary advices for each speciﬁc condition in patients with NETs,
underlining the importance of a nutritional approach to treat malnutrition in this setting. Further, we will
provide preliminary evidence coming from our data on the assessment of nutritional status in a single
cohort of patients with NETs.
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Introduction
Neuroendocrine tumours (NETs) include a heterogeneous
group of tumours which are relatively infrequent, although
an increased incidence and prevalence has been registered in
the last years (Yao et al. 2008; Halfdanarson et al. 2008;
Faggiano et al. 2012; Leoncini et al. 2017; Marciello et al.
2017). They affect the gastroenteropancreatic (GEP) system
and the bronchial tract, but in rare cases they also occur in
the ovaries, the urinary bladder, and other organs (Rindi and
Wiedenmann 2011). The most common sites of GEP NETs
are represented by the small bowel, rectum, and pancreas
(Dasari et al. 2017). NET-related symptoms are mostly due to
the secretion of either gastroenteropancreatic hormones or
biogenic amines (Rindi and Wiedenmann 2011). In fact the
clinical course of NETs can be characterized by various
hormone hypersecretion syndromes such as the carcinoid
syndrome or the hyperinsulinaemic hypoglycaemia syndrome
of insulinomas (Pape et al. 2008). However, over 70% of
patients have non-functioning NETs that never develop such
a syndrome (Faggiano et al. 2012).
Disease-related malnutrition is a frequently encountered
yet underecognized clinical phenomenon in patients with
NETs, with substantial prognostic and socioeconomic
implications both for affected patients and for caregivers.
Clinically important endpoints such as quality of life or
nutritional status have, however, been studied only very lim-
itedly (Davies et al. 2006) or non-systematically (Marrache
et al. 2007; Ekeblad et al. 2008). Body Mass Index (BMI) has
been reported to reﬂect a poor nutritional status that could
inﬂuence outcome in patients receiving transcatheter arterial
chemoembolization (Marrache et al. 2007) or in patients
with pancreatic NETs (Ekeblad et al. 2008).
The National Institute for Health and Care Excellence
(NICE) recommends malnutrition screening in all adult inpa-
tients and outpatients in at-risk groups (National Collaborating
Centre 2006). One of the most used tool to assess malnutrition
is the malabsorption universal screening tool (MUST) (BAPEN
2015). However, the assessment of malnutrition in patients
with GEP-NETs has been only reported in a single very recent
study to date (Maasberg et al. 2017).
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Currently, a comprehensive nutritional assessment of cancer
patients is recommended and it is based on several methods
such as the Subjective Global Assessment (SGA) (Detsky et al.
1984) or the Nutritional Risk Screening (NRS) (Kondrup et al.
2003), which now represent the most commonly applied nutri-
tional status assessment tools in clinical practice. Anthropomet-
ric measurements include not only measurements of height and
body weight, and the combination of both as the BMI, but also
mid-upper arm circumference (MUAC) and triceps skinfold
thickness (TST) as surrogates of malnutrition-associated loss of
muscle mass or subcutaneous fat deposits (Frisancho 1981).
Thus, the aim of this manuscript is to provide current evi-
dence on NET related metabolism derangements and symptoms
that could improve with an adequate nutritional management
and to provide the best nutritional approach to treat malnutrition
in this setting. Further, we will provide preliminary evidence
coming from our data on the assessment of nutritional status in
patients with NETs.
Nutrition and NETs
Similarly to other cancers, the overall goals of nutritional
approaches for a NET patient is to develop individualized
nutrition care plans, to promote optimal nutritional status, to
evaluate the effectiveness of nutritional interventions, and to
improve the quality of life of the patient during therapy,
depending also on whether or not the patient is symptomatic,
the stage of the disease, and the type of therapeutic manage-
ment. Thus, a skilled nutritionist should be part of the multidis-
ciplinary health care team in NETs management, adapting the
speciﬁc nutritional needs to the course of the disease. Despite
the pioneering work of Warner’s available at the Carcinoid
Cancer Foundation (Warner 2009), up to now there are no die-
tary guidelines speciﬁcally developed for NETs.
For patients with newly diagnosed asymptomatic NETs, it is
useful to follow recommendations by the healthy diet based on
the 2005 Dietary Guidelines Advisory Committee (DGA 2005)
(Table 1). However, due to the advancement of therapeutic and
diagnostic procedures, most NET patients, mainly GEP-NET,
are cancer survivors. According to the American Cancer
Society the major nutritional recommendation for all cancer
survivors regarding lifestyle is to eat at least ﬁve servings of
fruits and vegetables per day (Blanchard et al. 2008). In general,
patients with advanced cancer are often protein and fatty-acid
deﬁcient, with a close link with the decrease in skeletal muscle
mass and weight loss (Murphy et al. 2010). Changes in food
preferences and dietary habits are also commonly observed in
advanced cancer, thereby exacerbating nutrient insufﬁciencies
(Hutton et al. 2006). Sometimes, malnutrition due to cancer
therapy toxicity (mucositis, candidiasis, and nausea associated
with traditional chemotherapy) may worsen the nutritional sta-
tus of the patient. In addition, nutritional status may directly
affect both tolerance to and effectiveness of cancer treatments
(Prado et al. 2008).
Speciﬁc nutritional advices should be taken into account for
symptomatic NETs patients, in which the excessive hormonal
production by the tumour led to syndrome-speciﬁc gastro-
intestinal alterations (diarrhoea, malabsorption, nausea and
vomiting, to mention a few) and metabolic disturbances (hyper
or hypoglycaemia, dyslipidaemia), in addition to unspeciﬁc
symptoms such as anorexia, weakness, and weight loss. Dietary
advices for each speciﬁc condition are extensively reported in
the following sections. An additional nutritional consideration
in the management of patients with carcinoid syndrome is to
supplement the intake of foods rich in niacin (Shah et al. 2005).
The niacin deﬁciency, which can result from the increased tryp-
tophan metabolism into serotonin, can lead to dermatitis, diar-
rhoea, dementia, and pellagra. Supplementation with niacin
25 to 50 mg/day is recommended (Go et al. 2010). Further-
more, pancreatic enzymes, such as pancrease, creon, and
ultrase, and supplementations with fat-soluble vitamins A, D,
E, and K, are particularly recommended for patients with fat
malabsorption and steatorrhoea particularly related to therapy
with somatostatin analogues (SSAs)(Mamikuniam et al. 2009;
Pl€ockinger et al. 2004). About the use of nutraceuticals or other
dietary supplements there is scant evidence, and these products
should be used with caution since they may interfere with
anticancer agents.
There is considerable evidence that the Mediterranean diet
(MD) represents a dietary pattern suitable for the prevention of
non-communicable diseases, including cancer (Soﬁ et al. 2014).
A meta-analysis including both cohort and case-control studies
investigating the effects of adherence to MD on overall cancer
risk evidenced that a high adherence to a MD is associated with
a signiﬁcant reduction in the risk of overall cancer mortality
(10%), particularly from colorectal cancer (14%), prostate
cancer (4%) and aerodigestive cancer (56%) (Schwingshackl
and Hoffmann,2014). A few prospective cohort studies investi-
gated the association between diet composition and cancer
survival, reporting inconsistent results (Rock et al. 2012). For
example, some studies focused on the evaluation of the rela-
tionship between survival and single nutrients rather than die-
tary patterns (Rock et al. 2012; Jones and Demark-Wahnefried
2006). The beneﬁcial effects of nutritional interventions pro-
moting the Mediterranean food pattern could be extended to
NET patients. Future well-designed dietary intervention trials
on larger population samples are needed to deﬁne speciﬁc die-
tary guidelines for NETs.
Nutritional assessment of patients with NETs
There is convincing evidence that excess body fat is a cause of
several cancers (Byers and Sedjo 2015). Arnold et al. recently
Table 1. Recommendations by the 2005 Dietary Guidelines Advisory Committee.
Recommendations by the 2005 Dietary Guidelines Advisory Committee
Monitor your body weight to achieve health
Be physically active each day
Choose a variety of foods with, and among, the basic food groups, while not
exceeding your daily calorie limit
Increase daily intake of fruits and vegetables, whole grains, and non-fat or low-
fat milk and milk products
Keep food safe to eat
Decrease intake of saturated fat, trans fat, and cholesterol while increasing
foods rich in omega-3 fatty acids (ﬁsh)
Choose and prepare foods with less salt
If you drink alcoholic beverages, do so in moderation
From: US Department of Health and Human Services, US Department of
Agriculture. Dietary
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estimated that 3.6% of all incident cancers in the world in 2013
were caused by obesity (Arnold et al. 2015). It has been calcu-
lated that the increase in the risk of developing cancer for every
5 kg/m2 increase in BMI ranged from 9% to 56% (Kyrgiou
et al. 2017). The BMI is inexpensive and easy to measure, and
is considered a commonly used surrogate index for evaluating
adiposity. Nevertheless, BMI evaluates excess body weight
rather than excess body fat (Okorodudu et al. 2010), since it
does not measure body fat directly and poorly distinguishes
between fat mass and lean or bone mass (De Lorenzo et al.
2013). According to a recently published meta-analysis, BMI
was the most relevant risk factor for NETs development at all
investigated sites immediately after family history of cancer,
and followed by diabetes (Leoncini et al. 2016).
Nevertheless, NET-related weight loss due to malnutrition is
a frequently encountered yet under recognized clinical event,
with relevant prognostic and socioeconomic implications both
for affected patients and for caregivers (Norman et al. 2008).
Thus, waist circumference (WC) is recommended as an addi-
tional surrogate measure of fat distribution, due to its high cor-
relation with visceral fat (Bosy-Westphal et al. 2010). A
number of studies evidenced a strict association between WC
and cancer incidence (Kyrgiou et al. 2017). In particular, WC
has been associated with a higher risk of endometrial cancer
indicating that central obesity, which is linked to hyperinsuli-
naemia and type 2 diabetes, has a major role in the develop-
ment of this disease (Kyrgiou et al. 2017).
It is important to remind that the evaluation of the beneﬁcial
effect of therapeutic nutritional interventions should be moni-
tored not only via the BMI, because this may be misleading in
cases such as oedema (Maasberg et al. 2017). Bioelectrical Imped-
ance Analysis (BIA) and its derived parameter Phase Angle
(PhA) are non-invasive diagnostic tools widely used to evaluate
body composition in different populations (Barbosa-Silva et al.
2005; Norman et al. 2012). BIA measures resistance to an electri-
cal current and extrapolates ﬂuid and fat compartments from
this measurement (Barbosa-Silva et al. 2005; Norman et al.
2012). The parameters that can be measured include hydration
status (intracellular, extracellular, and total water content), body
fat mass, and electrolyte composition, which are essential in
determining the overall health status (Grundmann et al. 2015).
Malnutrition-associated patterns of body composition are
increased Extra Cellular Mass (ECM), which is largely deﬁned by
extracellular water, and decreased Body Cell Mass (BCM)
(Norman et al. 2012). The PhA is an indicator for cell membrane
integrity, water distribution between the intra- and extracellular
spaces and prediction of body cell mass, which is most com-
monly evaluated and correlated with nutritional status and sur-
vival rate (Paiva et al. 2010; Norman et al. 2012). Several studies
indicate that the use of BIA and PhA measures can aid in the
clinical management of cancer patients (Grundmann et al. 2015;
Haverkort et al. 2015).
The best use of BIA measurements is the evaluation of indi-
viduals over time to provide for longitudinal changes of PhA
along with disease progression, nutritional interventions, and
treatment. Very recently, we reported a novel association
between the adherence to the MD and PhA, independently of
sex, age, and body weight, recommending the nutrition assess-
ment as good clinical practice in the evaluation of PhA in
clinical settings (Barrea et al. 2017). Thus, BIA and PhA may
be particularly useful also to evaluate and predict outcomes
related to symptom management of patients with NETs, whose
nutritional status and symptoms are clearly affected by their
tumours. In particular, Maasberg et al. recently found signiﬁ-
cant differences in PhAs according to poorer nutritional status
as assessed by BIA in NET patients, as reﬂected in a decreased
PhA and an increased quotient of ECM to BCM (ECM/BCM
index), indicating the loss of BCM and an increase in ECM
(Maasberg et al. 2017).
Finally, the measurement of several circulating serum pro-
teins such as albumin or transferrin as surrogates of protein
turnover could also contribute to provide an overview of nutri-
tional status (Gupta and Lis 2010; Kyle et al. 2004).
In this context, skilled nutritionists can play a fundamental
role in the multidisciplinary NET team and their presence
should be recommended.
Gastroenterological symptoms
Diarrhoea and ﬂushing
Chronic diarrhoea and ﬂushing are among the most common
clinical manifestations of functioning NETs. They usually occur
in GEP NETs, the most common being carcinoids tumours,
and in advanced (metastatic) disease (Kaltsas et al. 2004;
Modlin et al. 2008).
Chronic diarrhoea is deﬁned as loose stools occurring more
than three times in one day and lasting for more than four
weeks (Schiller et al. 2017). It occurs as a consequence of exces-
sive production by the tumour of gastro-intestinal hormones,
peptides and amines (serotonin, dopamine, histamine, vasoac-
tive intestinal peptide (VIP), gastrin, glucagon, calcitonin and
prostaglandins, among others), which affect gastro-intestinal
(GI) functions (secretion, absorption and/or motility), leading
to various clinical syndromes (Kaltsas et al. 2004; Modlin et al.
2008; Boutzios and Kaltsas 2015) (Table 2). According to cur-
rent characterization, chronic diarrhoea may be subdivided
into different categories, which may overlap, by pathophysiol-
ogy (e.g. secretory, malabsorptive, hypermotility forms, to men-
tion a few) and by stool characteristics (e.g. watery or fatty)
(Schiller et al. 2017). The majority of NETs patients are charac-
terized as having a watery diarrhoea due to decreased net
absorption of water by the intestine, the so-called secretory
diarrhoea. Indeed, bioactive amines and peptide hormones,
when produced in excess, stimulate excessive mucosal secretion
of ﬂuid from the intestine, leading to diarrhoea. In this type of
diarrhoea intestinal ﬂuid secretion is isotonic with plasma and
the stool electrolyte composition is similar to that seen with
cholera (Schiller et al. 2017). Neither there is structural damage
nor inﬂammation. Secretory diarrhoea occurs independently of
dietary intake: it may be postprandial, mostly after large and
fatty meals, but it persists despite fasting and at night. Certain
foods and beverages may trigger diarrhoea and/or ﬂushing, as
well as emotional and/or physical stress does (Table 3). In
some GEP NETs (somatostatinomas and less frequently gastri-
nomas), diarrhoea is associated to steatorrhea (i.e. the presence
of large quantities of unabsorbed fat in the stool) due to fatty
acid malabsorption (Kaltsas et al. 2004; Modlin et al. 2008).
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Also, certain substances, such as calcitonin and prostaglandins,
may cause GI hypermotility and marked reduction in the tran-
sit time of colonic contents, further contributing to cancer-
associated diarrhoea (Rambaud et al. 1988). Finally, beside the
tumour production of an excess of bioactive substances, diar-
rhoea may be the consequence of surgical and/or medical ther-
apies, so that also the management of the tumour can have
nutritional implications. For instance, the surgical resection of
the bowel causes a direct loss of absorptive surface and may
also lead to either accelerated (e.g. post-vagotomy diarrhoea) or
slowed (impaired motility causing bacterial overgrowth) GI
transit, thereby predisposing to diarrhoea and steatorrhea
(Schiller et al. 2017). SSAs, that offer the best therapeutic option
for managing clinical symptoms in patients with GEP NETs,
have well-known GI side effects (diarrhoea and steatorrhea,
gallstones, constipation, gas and dismotility) caused by the
inhibitory effect of somatostatin on GI and pancreatic func-
tions (Chung 2016). Systemic chemotherapy (streptozocin,
platinum salts, 5-ﬂuorouracil, irinotecan, temozolamide, and
capecitibine, to mention a few) and combination therapy with
interferon, mTOR (everolimus) or tyrosine-kinase (sunitimib,
vandetanib and cabozantinib) inhibitors, that are currently
used in NETs, have additional GI side effects including diar-
rhoea, anorexia and weight loss, nausea and vomiting, and liver
function abnormalities (Stein et ak. 2010; Chung 2016).
Currently, the SSAs octreotide, lanreotide and pasireotide
are used to control symptoms (including diarrhoea and ﬂush-
ing) of patients with GEP NETs (Gut et al. 2017; Chung 2016).
However, a not negligible number of patients do not achieve
Table 2. Clinical syndromes associated with chronic diarrhoea in NETs.
TUMOUR
SECRETION PRODUCT/
BIOCHEMICAL MARKER DIARRHOEAL SYMPTOMS ASSOCIATED SYMPTOMS AND SIGNS
GEP- NET
MIDGUT TUMOURS
Carcinoid (carcinoid syndrome) serotonin and tachykinins/
24 hours urinary 5-hydroxyndoleacetic
acid (5-HIAA), the primary catabolic
product of serotonin
Chronic secretory watery diarrhoea after
eating. It may be triggered by certain
foods or alcohol and persists even
during fasting and at night.
Flushing, wheezing and
bronchoconstriction, sweating,
weight loss, hypertension, right heart
disease
FOREGUT TUMOURS
VIPoma (Verner-Morrison syndrome) vasointestinal peptide (VIP)/ serum VIP Chronic secretory watery diarrhoea with
excessive loss of water and electrolytes.
Diarrhoea is really profuse and occurs
even during fasting and night-time.
Dehydration, marked hypokalaemia,
achlorhydria, acid-base disturbances,
weight loss, ﬂushing, hypotension.
Gastrinoma (Zollinger-Ellison
syndrome)
Gastrin/ Chronic or intermittent secretory
diarrhoea, with or without
steatorrhea. It
hyperchlorhydria, heartburn, nausea and
vomiting, severe peptic ulceration,
weight loss
Serum gastrin and gastric pH is responsive to proton-pump inhibitors
Glucagonoma Glucagon/ Chronic or intermittent secretory
diarrhoea (in less than 15% of patients)
Necrolytic migratory erythema,
stomatitis, weight loss, diabetes
mellitus
Serum glucagon
Somatostatinoma Somatostatin/ diarrhoea and steatorrhea gallbladder dysfunction and gallstones
(cholelitiasis), weight loss, impaired
glucose tolerance/diabetes mellitus
Serum somatostatin
NON–GEP NET
Medullary Thyroid Cancer Calcitonin, Prostaglandins E2 and F2a,
serotonin, kallikrein and substance P/
Chronic or intermittent diarrhoea. It
may be hypersecretory and/or due
to gastrointestinal hypermotility. It
occurs after eating, but does not
subside with fasting and may be
triggered by certain foods and
alcohol
Flushing, bone pain, itching (pruritis),
weight loss
Serum calcitonin
Table 3. Foods and beverages that may trigger diarrhoea and/or ﬂushing in NETs
patientsx.
Determinants Foods and drinks
Size of the meal Large meals (weddings, Christmas,…)
Fat content Fatty foods
“Hot” Spices Pepper, cayenne pepper, mustard, curry
Amine content* High in amines:
(tyramine, dopamine and others) Aged cheese (Cheddar, Camembert,
Stilton)
Alcohol, fermented drinks (beer),
vinegar
Smoked/salted ﬁsh and meat
(sausages, corned beef, herring)
Yeast and yeast extracts
Broad bean, soybean products, soy
sauce
fermented-tofu, miso, sauerkraut
Any spoiled protein food
Moderate in amines:
Coffee (large amounts) and caffeine-
containing drinks
Carbonates drinks (soda)
Chocolate (large amounts)
Nuts (brazil nuts, coconuts, peanuts)
Tomatoes (cooked tomatoes are
better tolerated than raw)
Avocado, banana, raspberries,
pineapple
Some pizzas
xCarcinoid, VIPoma and medullary thyroid cancer patients.
Tyramine and other amines are usually present in aged, fermented and spoiled
protein products. Their effects are dose-related. Small amounts of amines-con-
taining foods may not trigger any reactions. Content of serotonin in food is not
relevant to the above mentioned reactions, but it affects the urine 5-HIAA levels,
causing false positive results.
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adequate symptom relief with SSAs alone, and new therapeutic
options (i.e. telotristat ethyl) are under investigation (Kulke
et al. 2017). In patients refractory to SSAs, as well as in patients
who experience the GI side effects of SSAs, anti-motility agents
(loperamide and opiates) may be used for symptomatic
improvement of NETs-related diarrhoea (Gut et al. 2017).
They should represent the initial therapy in patients with med-
ullary thyroid cancer and diarrhoea (Schlumberger et al. 2012).
Also non-dairy, multi-strain probiotics that contain biﬁdobac-
teria or lactobacillus strains may be of help. In patients com-
plaining of steatorrhea, pancreatic enzyme replacement therapy
should be prescribed to improve nutrients absorption.
In addition to medical therapies, dietary and nutritional inter-
vention can improve GI discomfort, global health status and
quality of life of symptomatic patients. There are several
nutritional key points to consider for symptomatic NETs
patients suffering from diarrhoea (Warner 2009; Go et al. 2010).
First, water and ﬂuids intakes are crucial in such patients to pre-
vent dehydration and revert electrolytes alterations (hypokalae-
mia). The recommended daily intake of water/ﬂuids is at least
two quarts per day. Potassium ﬂuids and foods may also be a
useful addition to the diet and in severe cases (i.e. VIPomas)
electrolyte replacements should be provided. Alcoholic bever-
ages, carbonates soft drinks, coffee and caffeine-containing
drinks should be avoided or consumed sparingly, since they may
trigger diarrhoea due to their amines content (Table 3). For the
same reason, also “hot” spices and certain foods should be
avoided to prevent diarrhoea and ﬂushing as well (Table 3).
However, the effects of amine-containing foods and beverages
are dose related, and small amounts may not trigger reactions
(severe reaction 10–25 mg tyramine per meal; moderate reaction
6–10 mg tyramine per meal) (Warner 2009). Moreover, the
types of foods/drinks that cause this reaction are individual in
nature and the reaction may strongly differ from patient to
patient. It should be advisable each patient to record on a diary
food intake and the symptoms experienced afterwards. The size
of the meal and the fat content may also trigger symptoms such
as diarrhoea, steatorrhea and ﬂushing, likely via stimulation of
gut hormones release. Large meals and high fatty foods should
be avoided: symptomatic patients should eat little and often
and keep a moderately low intake of fat, mostly if they are
affected by steatorrhea. Regular milk and dairy products (cream,
butter, cheese, whole milk yoghurt) should be replaced, at least
in part, by non-fat or low-fat milk and milk products, as well as
by lactose-free products.
There are also several nutritional advices concerning die-
tary sources of ﬁbre, that may help the patient to better con-
trol diarrhoea. Even if the diet should be high in fruit,
vegetables and grains (5 to 10 servings/day) as suggested in all
cancer patients, symptomatic NETs patients should reduce
insoluble ﬁbre and increase soluble ﬁbre in the diet. Also, they
should favor cooked and peeled fruit and vegetables instead of
raw vegetables, fresh and dried fruit and pickles; fruit juice
“without bits” instead of pure fruit smoothies (Table 4)
(Warner 2009; Go et al. 2010).
Nutrition intervention may be useful also in preventing
ﬂushing, that is commonly associated to diarrhoea in patients
suffering from carcinoids (typical and atypical forms), VIP-
omas and medullary thyroid cancer. Cutaneous ﬂushing,
deﬁned as a sensation of warmth accompanied by visible red-
dening of the skin, results from changes in cutaneous blood
ﬂow due to vasoactive substances secreted by the tumour (5-
hydroxytryptamine, histamine, substance P, serotonin, cate-
cholamines, prostaglandins, kallikrein, kinins, tachykinins,
VIP, calcitonin) (Hannah-Shmouni et al. 2016). As well as diar-
rhoea, ﬂushing in NETs may be triggered by certain foods and
beverages, via stimulation of gut hormones release or via
amines-containing food (Table 3), as well as by any stimuli that
increases adrenergic activity (physical and/or emotional stress,
certain drugs) (Warner 2009; Go et al. 2010).
Pyrosis
Gastrinoma is a rare GEP NET mainly arising from duodenum
(75%) and pancreas (25%), which can be sporadic or occur as a
component of the genetic disorder multiple endocrine neopla-
sia (MEN)-1 syndrome (20%-30% of cases). Excessive secretion
of gastrin may cause the Zollinger-Ellison syndrome, with pep-
tic ulcer disease and serious reﬂux oesophagitis. Gastric pyrosis,
abdominal pain, and digestive disorders are the most important
symptoms reported by patients with gastrinomas (Zhang et al.
2016). The ﬁrst therapeutic approach is based on lifestyle
change and on correct diet to reduce the acid secretion and
control pyrosis. Obesity, smoking, alcohol abuse and diet are
the most important factors involved in acid secretion control.
In addiction high dietary ﬁbre intake and moderate physical
activity seem to improve symptoms (Ness-Jensen et al. 2016;
Kaltenbach et al. 2006).
In general:
 Weight reduction in obese or overweight patients can
reduce acid exposure;
Table 4. Nutritional advices in NETs patients suffering from diarrhoea.
Foods and drinks
TO BE PREFERRED
Foods and drinks TO BE
AVOIDED/REDUCED
Still water and sports drinks Coffee and caffeinated beverages
Tea and lemon Carbonates and sugary drinks
Lactose-free beverages and products Milk and dairy products
Fish (blue-ﬁsh and other oily ﬁshes) Meat, eggs
Potatoes, rice and rice cream, pasta Foods high in sugar and fat
Soluble ﬁbre High insoluble ﬁbre foods
Cooked and peeled fruit Wholegrains
Applesauce Raw vegetables
High fruit jams Cabbage, mushrooms, artichokes
Oats Legumes with peel
Pureed legumes and vegetables
(carrots, zucchini, Alcohol
cucumbers,…) “Hot” Spices
Food and drinks containing potassium Pepper, cayenne pepper, mustard,
curry,
Ripe bananas (small amounts) Chocolate
Apricots
Plums
Kiwi
Pears
Fresh ﬁgs
Fruit juice “without bits”
Watered-down orange juice
Foods that contain salt
pretzels and crackers
clear broth soup
Honey/ Molassas
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 Tobacco smoking cessation will normalize the lower oeso-
phageal sphincter pressure and salivary bicarbonate
production;
 Alcohol consumption may increase acid secretion
through gastrin stimulation;
 Avoidance of foods that may precipitate acid secretion,
such us coffee, chocolate, peppermint, citrus, carbonated
drinks, spicy and fatty food (Ness-Jensen et al. 2016;
Kaltenbach et al. 2006).
Constipation
Constipation is medically deﬁned as less than three bowel
moments per week and is considered severe if a person has less
than one bowel movement per week. Symptoms of bloating
and gas may accompany constipation (Anthony 2010). Consti-
pation is a less common condition than diarrhoea in NETs
patients. Most of times it occurs in non-functioning GEP NETs
as a consequence of intestinal obstruction by the tumour mass
or represents a side effect of medical therapies of either func-
tioning or non-functioning NETs (SSAs, chemotherapy, evero-
limus, sunitinib) (Kaltsas et al. 2004; Modlin et al. 2008; Chung
2016). Noteworthy, longstanding constipation is a rare compli-
cation of phaeochromocytoma and paraganglioma. The hyper-
secretion of catecholamines by the tumour may reduce the
peristaltic activity of the gastrointestinal tract, resulting in
chronic constipation and intestinal pseudo-obstruction
(Thosani et al. 2015).
In NETs patients with chronic constipation nutritional and
dietary intervention are aimed to prevent dehydration and help
bowel movements. Water/ﬂuids intake should be increased
over the normal habit of the patient and high ﬁbre diet should
be followed (whole grains, vegetables and fruit with high ﬁbre
content), avoiding gas-forming foods (e.g. onions, garlic, cab-
bage, pulses, cauliﬂower, broccoli, nuts) (Table 5). Regular and
moderate physical activity/gentle exercise may also help regu-
late bowel motility. Stimulant laxatives, including herbal prod-
ucts, should be used as a last resort (Warner 2009).
Metabolic effects
Hypoglycaemia
Hypoglycaemia is the distinctive feature of insulinoma, the
most common functioning NET of the pancreas, with an
annual estimated incidence of 1–4 per million population
(de Herder et al. 2006; Shin et al. 2010). Approximately 90%
of insulinomas are solitary, more than 90% are benign, and
5–10% are associated with MEN-1. Causing intermittent over-
secretion of insulin, insulinomas classically present with recur-
rent episodes of spontaneous hypoglycaemia. Early recognition
and diagnosis are often challenging. Historically, diagnostic
workﬂow starts from the presence of Whipple’s triad, which
includes: 1) symptoms and/or signs of hypoglycaemia; 2) low
plasma glucose ( 2.2 mmol/L;  40 mg/dL); 3) recovery of
symptoms and/or signs after administration of glucose.
Glucose is an obligate metabolic fuel for the brain, and a vir-
tually continuous supply of glucose from the circulation is fun-
damental for survival. Since blood-to brain glucose transport is
a direct function of blood glucose concentration, prolonged or
profound hypoglycaemias can produce important metabolic
derangements and be life-threatening. Generally, symptoms of
hypoglycaemia are categorized as either neuroglycopenic or
neurogenic (Table 6).
When technically feasible, complete surgical excision is the
treatment of choice. However, for patients who are not candi-
dates for surgical resection (eg, malignant insulinomas with
unresectable metastatic disease) or those who are awaiting sur-
gery, dietary modiﬁcation designed to prevent prolonged peri-
ods of fasting becomes of paramount importance in the
management of insulinomas.
There is little evidence about the best dietary strategy for people
with insulinoma, and nutritional advice is mainly based on trust in
the expertise. Most of the available studies deal with the manage-
ment of hyperinsulinemic hypoglycaemia after bariatric surgery or
postoperative dumping syndrome. However, in these patients,
oversecretion of insulin is triggered by rapid absorption of glucose
and is reactive to the ingestion of a meal, whereas insulin produc-
tion is completely autonomous in patients with insulinoma.
The goal of dietary therapy is to prevent prolonged periods of
fasting by consuming small, frequent meals throughout the day
and night. Unless a body weight reduction is needed, a diet of ade-
quate calories (30 Kcal/kg) consisting of a high protein, variable fat,
and low carbohydrate content has proved satisfactory. Such a diet
should be administered in regulated frequent feedings (splitting
Table 5. Nutritional advices in NETs patients to relief constipation.
Foods and drinks
TO BE PREFERRED
Foods and drinks TO BE
AVOIDED/REDUCED
Still water (at least two liters a day) Coffee and caffeinated
beverages, Tea
Warm drinks (warm milk,…) Carbonated, sparkly and cold
drinks
High ﬁbre foods and beverages White bread and rice,
persimmon
Wholegrains
Bran, all-bran, cornﬂakes Apples, bananas, lemon
Legumes (beans, lentils, peas)
Vegetables (artichokes, lettuce, fennel,
aubergine, salads)
Gas-forming foods (onions,
garlic, cabbage, cauliﬂower,
Fresh fruit (kiwi, pears, prunes, broccoli,nuts)
plums, berries)
Dried fruits (ﬁgs, raisins, and dried apricots) Read meat
Prunes juice Foods high in fat
Sweet potatoes and roast/crisp potatoes Fast foods, chips
Seed (sesame, pumpkin, sprinkle, ﬂax seeds) Processed foods/ Frozen meals
Honey White sugar
Chewing gum, chocolate
Table 6. Typical symptoms and signs of hypoglycaemia, related to neuroglycope-
nia or to neurogenic (autonomic) surge.
Neuroglycopenic Adrenergic Cholinergic
Visual disturbances (diplopia,
blurred vision)
Arousal, anxiety Sweating
Altered mental status,
confusion, abnormal
behaviour, amnesia
Palpitations Hunger
Nightmares/bizarre dreams Weakness,
lightheadness
Paraesthesias, feeling of
warmth
Psychomotor abnormalities Tremors
Weakness, fainting, dizziness Nausea
Seizures, loss of consciousness,
coma
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food intake into ﬁve to six light-meals), since shortening the num-
ber of hours between feedings is perhaps more important than the
composition of the diet (dePeyster and Gilchrist 1954; Kandasw-
amy et al. 2016). A high protein diet provides a source of glucose
that may bemetabolized over a prolonged period and causes a slow
release of glucose into the bloodstream, thus reducing secondary
hypoglycaemia from reactive insulin stimulation. Furthermore, it
can prevent weight gain and obesity which is another typical mani-
festation of insulinomas, since patients eat frequently to prevent
symptoms of hypoglycaemias. Low glycaemic index and complex
carbohydrates can helpmaintaining blood glucose levels for longer,
reduce the glycaemic load, and therefore the symptoms of post-
prandial hypoglycaemia. Alcohol consumption should be avoided,
since it reduces hepatic glucose production. In some circumstances,
partial or total parenteral nutrition may become necessary, to the
detriment of amajor effect on daily life.
During hypoglycaemic episodes, oral administration of rapidly
absorbable forms of carbohydrates with a high glycaemic index
such as fruit juices, soft drinks, milk with added sucrose, candies
or other snacks, or glucose tablets, are suited (up to 15–30 g of
glucose), whereas parenteral glucagon or intravenous dextrose
infusions are needed for the emergency treatment of hypoglycae-
mic coma, or when the patient is unwilling or unable to take car-
bohydrates orally. However, according to preliminary evidence
from animal models, posttreatment hyperglycaemia after an epi-
sode of profound hypoglycaemia may contribute to neuronal
damage and should be avoided (Cryer et al. 2009).
Hyperglycaemia
Varying degrees of imbalance of glucose metabolism up to overt
DM with symptomatic hyperglycaemia may develop secondary
to NETs, especially in patients with underlying genetic diabetic
predisposition (Resmini et al. 2009; Minuto et al. 2014). Hyper-
glycaemia may result from: a) a direct tumour mass effect on the
pancreas, reducing insulin production; b) surgical treatment
(total or partial pancreatectomy); c) overproduction of substances
interfering with insulin secretion (e.g. catecholamines, somato-
statin, or hypokalemia) and/or action (e.g. glucagon, glucocorti-
coids, catecholamines, ghrelin, or growth hormone), as in
patients with pheochromocytoma, VIPoma, glucagonoma, soma-
tostatinoma, or with paraneoplastic syndrome; d) altered coun-
terbalance between glycoactive hormones due to medical therapy
(somatostatin analogues, interferon, steroids given with tradi-
tional chemotherapy, and/or everolimus)(Gallo et al. 2017).
Paradoxically, considerable improvements in treatment
strategies, and consequently in life expectancy, have increased
the number of patients with NETs developing diabetes and
even diabetic complications, thus emphasizing the importance
of appropriated diabetes management also in this setting.
Malnutrition is very commonly seen in cancer patients (and in
patients with NETs), being responsible for an excess of morbidity
and mortality, negatively inﬂuencing the outcomes of oncologic
treatments, and worsening the quality of life (Norman et al.
2008). Malnourished patients should timely receive nutritional
assessment and support, independently from the presence of DM
and glucose control.
For people who are not losing weight, have symptoms con-
trolled, are otherwise well, and have a long life-expectancy, a
healthy balanced diet has an integral role in overall diabetes man-
agement, just like in every patient with DM (NHS Foundation
Trust 2014; American Diabetes Association 2017; Evert et al.
2004). Since there is not a one-size-ﬁts-all eating pattern for all indi-
viduals with DM, every patient should receive individualizedmedi-
cal nutrition therapy with the following goals: 1) to achieve and
maintain bodyweight goals; 2) to attain individualized glycaemic,
blood pressure, and lipid goals; and 3) to delay or prevent diabetes
complications. Furthermore, appropriated advices should be given
in order to maintain the pleasure of eating and to address individ-
ual needs based on personal and cultural preferences. In overweight
and obese patients a sustained reduction  5–7% of initial body
weight, to be attained with dietary programs achieving a 500–750
kcal/day energy deﬁcit, has been shown to be adequate.
As a general approach, healthful eating patterns containing
nutrient-dense, high quality foods (such as whole grains, vege-
tables, fruits, legumes, low-fat dairy, lean meats, nuts, and
seeds) in appropriate portion sizes should be emphasized, with
less focus on speciﬁc nutrients or single foods. Indeed, studies
examining the ideal amounts of daily carbohydrate, protein,
and fats intake for people with DM are rather inconclusive.
In general:
 Monitoring carbohydrate intake and considering the
blood glucose response to dietary carbohydrate (glycae-
mic index and glycaemic load) improve postprandial glu-
cose levels;
 Replacing reﬁned carbohydrates and added sugars with
whole grains, legumes, vegetables, and fruits should be
encouraged;
 Sugar sweetened beverages and foods with added sugars
should be strongly discouraged;
 Protein intake should be individualized based on current
eating patterns, taking into account kidney function;
 Trans fats should be avoided;
 Foods rich in long-chain v-3 fatty acids are recom-
mended to prevent or treat cardiovascular disease;
 Alcohol consumption should be moderated ( 1 drink/
day for adult women,  2 drinks/day for adult men);
 Sodium consumption should be limited to< 2,300mg/day.
Among healthful eating patterns, a Mediterranean-style diet
rich in monounsaturated fatty acids (predominantly from olive
oil), fruits, vegetable, whole-grains, and ﬁsh, is associated with
a high degree of satiety, can improve both glycaemic control
and blood lipids, and delay the need for antihyperglycaemic
drug therapy (Esposito et al. 2009).
Lipids
High cholesterol levels have been detected in patients with can-
cer, due to the tumour per se or as a consequence of cancer
therapy (Ray and Husain 2001; Qadir and Malik 2008; Utsumi
et al. 2007; Namiki et al. 2007).
There is little evidence on the association between NETs and
dyslipidaemia. Everolimus is currently used for the treatment of
NETs. An increase of total cholesterol with everolimus has been
reported by several studies (Baur et al. 2011; Brattstron et al. 1998).
Treatment with everolimus is also associated with a signiﬁcant
increase of plasma triglycerides (Lorber et al. 2005; Vitko et al.
2004). This association could be explained by the fact that mTOR
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Complex 1 (mTORC1) controls lipid metabolism by different
ways. Several data indicate that mTORC1 increases the activity of
the transcription factor sterol regulatory element-binding protein-
1c (SREBP-1c), upregulating the expression of enzymes involved
in lipogenesis (acetyl-CoA carboxylase, fatty acid synthase, and
stearoyl-CoA desaturase). It has been shown that impairment of
mTORC1 activity with rapamycin blocks the SREBP-1c induced
expression of lipogenic enzymes. mTORC1 has been shown to
increase PPARgamma expression, to promote adipogenesis (Zhang
et al. 2009), and to increase the activity of lipin 1, which is a phos-
phatidic acid phosphatase promoting triglyceride synthesis and
enhancing the PPARgamma adipogenic activity. Some traditional
chemotherapy agents also alter lipid proﬁle: e.g., doxorubicin can
reduce high density lipoprotein cholesterol (HDL-C) and apolipo-
protein A1 (apoA1) levels, and rise apolipoprotein B (apoB) levels,
probably via a reduced expression of the ATP binding cassette
transporter A1 (ABCA1) in liver cells through downregulation of
the liver X receptor a (LXRa) and peroxisomal proliferator acti-
vated receptor g (PPARg) transcription factors (Sharma et al.
2016).
Therefore the assessment of lipid proﬁle is of paramount
importance in patients with NETs treated with everolimus. In
fact an early diagnosis of dyslipidaemia could allow a personal-
ized nutritional approach contributing to reduce the increased
cardiovascular risk.
Foods to avoid for patients preparing for the 24-h
urine 5HIAA test
Preparing for the 24-hour urine 5HIAA test some medication
as some drugs that can interfere with 5HIAA measurements
should be discontinued (eg, cough syrup and reserpine, levo-
dopa, MAO inhibitors, methyldopa, phenothiazines, and tricy-
clic antidepressants). Similarly, foods containing 5-
hydroxytryptamine (serotonin), the precursor of 5HIAA,
should be avoided for three days before the test and whilst col-
lecting the sample of urine (see Table 7).
Nutritional habits among a single cohort of patients
with GEP NETs
Shown below, we report the metabolic and diet proﬁle of a sin-
gle cohort of patients with GEP-NETs, followed up at the Neu-
roendocrine tumours Unit of the “Federico II” University of
Naples and who participated to a dedicated nutritional survey.
Functioning GEP NETs were not included with the aim to
eliminate the potential confounding effect of functioning
tumours (eg, insulinomas) on metabolic variables. Among the
50 patients with sporadic non-functioning GEP NETs, 37
entered this study. Five patients were excluded for insufﬁcient
data available, 2 patients were cachectic at time of ﬁrst visit,
and 6 patients were older than 70 years.
The diagnosis of GEP NET was histologically documented
for all patients and deﬁned according to the 2010 WHO classi-
ﬁcation criteria. Staging was deﬁned according to the TNM sys-
tem updated to 2010 (Bosman 2010).
Clinical characteristics such as weight, height, WC, arterial
blood pressure, dietary pattern, and metabolic parameters were
evaluated at time of diagnosis of the GEP NET.
Metabolic Syndrome was deﬁned according to the revised
NCEP ATP III (2001), and three or more criteria were consid-
ered: plasma glucose concentration 100 mg/dL, WC > 88 cm,
serum high-density lipoprotein (HDL) concentration < 50 mg/
dL, blood pressure 130/85 mmHg, and serum triglyceride
concentration 150 mg/dL.
A validated 14-item questionnaire for the assessment of
adherence to the Mediterranean diet (PREDIMED) was
recorded for all the enrolled subjects. Brieﬂy, for each item a
score of 1 or 0 was assigned; PREDIMED score was calculated
as follows: 0–5, lowest adherence; score 6–9, average adherence;
score 10, highest adherence (Martınez-Gonzalez et al.2012).
Therefore, the patients completed a 7 days diary to evaluate
macronutrients distribution and diet composition.
Metabolic parameters evaluated were: fasting plasma glu-
cose, serum total cholesterol, serum low-density lipoprotein
(LDL) and HDL cholesterol, serum triglycerides, selenium, reti-
nol, tocopherol and vitamin C levels.
In our group, a G1 NET diagnosis was reported in 20
patients (54%) and G2 in 17 (46%). Disease progression was
reported in 5.4% of patients during the follow up, and 89,9% of
them were treated with somatostatin analogues. Sporadic
tumours were reported in 51.3% of the cases, and 48.7% had a
diagnosis of MEN-1. Metastatic status was reported in 27% of
patients, at time of diagnosis. The anthropometric and meta-
bolic proﬁle of the cohort are reported in Table 8.
In our cohort, 27% of the patients presented a good adher-
ence to the Mediterranean diet, 56% a moderate adherence,
and 16.2% a poor adherence. A poor vitamin (Ascorbic acid
78.4§48.4 mg) and selenium (23.8§14.8 mcg) status were reg-
istered, relative to standard values.
Subjects with high blood pressure presented higher levels of
Ki-67 index (5.0§5.6 vs 3.7§2.6; p D 0.004), and a higher
tumour size at diagnosis was reported in patients with diabetes
(2.3§4.1 vs 0,85§1.3; p<0.001). A correlation analysis was per-
formed: a positive association between tumour size and total
and LDL cholesterol levels was reported (r D 0.419, p<0.001;
r D 0.498, p D 0.002; respectively).
No signiﬁcant differences were reported about diet composi-
tion in presence or absence of metastases at diagnosis (Table 9).
In addition, we compared the diet composition between sub-
jects with sporadic GEP NETs and MEN1 patients: no signiﬁ-
cant differences were seen, except for selenium levels (17.2§
7.1 vs 30.7§17.9, p D 0.005).
Overweight and obesity were very common in our cohort of
patients with GEP NETs (40.6% and 28.1% of patients, respec-
tively). Furthermore, hypertension and diabetes were reported in
Table 7. Foods to avoid whilst collecting urine samples for 5HIAA test (Available at
http://www.carcinoid.org).
Bananas
Pineapple and its juice
Tomatoes and all tomato products
Plums
Aubergines
Eggplant
Avocados
Kiwi
Fruits in general
Nuts, especially walnuts
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40.5% and 25% of the patients, respectively. Therefore we can con-
clude that a metabolic disease was very common in our patients
with non-functioning GEP NETs, at diagnosis. In particular, meta-
bolic disorders were associated withmarkers of disease severity: Ki-
67 index was higher in patients with high blood pressure, and a
greater tumour size at diagnosis was reported in subjects with dia-
betes. Lastly a positive association was observed between total and
LDL cholesterol with tumour size. These data suggest that meta-
bolic syndrome may associate with NET greater severity. The larg-
est part of our group presented a medium grade of adherence to
theMediterranean diet, albeit we did not observe any difference rel-
ative to the presence of metastases or the hereditariness of the dis-
ease (sporadic vsMEN-1).
In conclusion, these preliminary data suggest that the meta-
bolic proﬁle may correlate with disease severity. In this context,
a cooperation between Endocrinologists, Oncologists, and
Nutritionists can represent an innovative and important
approach to improve the follow up and prognosis of patients
with GEP NETs.
Conclusions
NETs are characterized by symptoms that are related to the
tumour per se but also to anticancer drugs. Most of these symp-
toms such as diarrhoea, ﬂushing, pyrosis, and constipation can
be alleviated by a tailored nutritional approach. A nutritional
treatment could be also of paramount importance in the man-
agement of metabolic complications represented by hypo/
hyperglycaemia and dyslipidemia. Thus, the nutritional coun-
selling is mandatory before and during cancer treatments in
patients with NETs in order to identify the best nutritional
approach that not only will improve the symptoms but also
contribute to make anticancer therapy successful.
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Table 8. Anthropometrics and metabolic parameters of participants.
Parameters Mean§SD
Anthropometric parameters
Weight (Kg) 70§14.3
BMI (Kg/m2) 27§4.2
Normal weight (%) 31.3%
Overweight (%) 40.6%
Obesity (%) 28.1%
Waist circumference (cm) 95.1§17.2
Metabolic parameters
Systolic Blood pressure (mmHg) 122.7§16.5
Diastolic Blood pressure (mmHg) 77.5§8.3
Hypertension (%) 40.5%
Glycaemia (mg/dL) 111.2§27.2
Diabetes (%) 24.3%
Total cholesterol (mg/dL) 173.6§36.2
HDL cholesterol (mg/dL) 52§12.7
LDL cholesterol (mg/dL) 99§29.7
Hypercholesterolemia (%) 13.5%
Triglycerides (mg/dL) 112§44
All anthropometric measurements were taken with subjects wearing only light
clothes and without shoes. For each subject, weight and height were measured
to calculate BMI [weight (kg) divided by height squared (m2), kg/m2]. Height was
measured to the nearest 1 cm using a wall-mounted stadiometer. Body weight
was determined to the nearest 50 g using a calibrated balance beam scale. The
degree of obesity was established according to a scale based on BMI cut-off
points: 30–34.9 kg/m2 (grade I obesity), 36–39.9 kg/m2 (grade II obesity), and
40 kg/m2 (grade III obesity, or severe obesity), respectively. Waist circumfer-
ence (WC) was measured to the closest 1 cm with non-extensible tape at the
natural indentation or at a midway level between the iliac crest and the lower
edge of the rib cage if no natural indentation was visible. The measurement was
made with the subject standing upright, feet together, and arms hanging freely
at the sides. Systolic blood pressure (SBP) and diastolic blood pressure (DBP)
were measured with a previously calibrated mercury sphygmomanometer, and
the mean value of three measurements was calculated.
Table 9. Differences in diet composition between patients with metastatic disease
at diagnosis and patients with no metastases.
Parameters
Metastatic
disease nD 10
No Metastatic
disease n D 27
p
value
Total energy(kcal) 1483.6 § 382.2 1595.3 § 371.1 0.425
Total Carbohydrates (g) 199.6 § 57.9 206.0 § 52.1 0.750
Total Carbohydrates (%) 53.7§ 5.3 51.5§ 4.0 0.201
Simple Carbohydrates(g) 122.1 § 40.6 135.9 § 37.5 0.338
Complex carbohydrates(g) 248.7 § 64.1 262.8 § 75.5 0.578
Fiber (g) 16.1§ 8.5 13.7§ 5.2 0.312
Total Protein (g) 67.2§ 22.0 74.1§ 20.0 0.373
Total Protein (%) 17.9§ 1.6 18.5§ 2.3 0.340
Total fat (g) 46.2§ 14.1 52.7§ 12.9 0.191
Total Fat (%) 28.3§ 5.6 29.8§ 3.9 0.372
MUFA (g) *

64.1§ 27.6 75.5§ 28.1 0.880
PUFA (g) *

2.2§ 0.9 2.7 § 1.0 0.196
SAFA (g) *

55.8§ 27.5 65.0§ 19.4 0.267
Omega 3 0.3§ 0.16 0.3 § 0.18 0.869
Omega 6 1.8§ 0.7 2.3 § 0.9 0.138
Cholesterol (g) 162.4 § 25.0 185.7 § 83.8 0.205
Ascorbic acid (mg) 88.7§ 76.2 74.6§ 34.3 0.442
Retinol (mcg) 888.2 § 693.1 569.0 § 319.1 0.006
Tocopherol (mg) 5.2§ 3.1 5.2 § 2.0 0.993
Selenium (mcg) 19.9§ 12.2 25.2§ 15.8 0.299
SCORE Mediterranean Diet 8.7§ 2.8 7.8 § 1.7 0.308
MUFA: MonoUnsatured Fatty Acid; PUFA: PoliUnsatured Fatty Acid; SAFA: Satured
Fatty Acid
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